跳到正文
原文
Endpoints News 生物医药· Kyle LaHucik·· 2026-10-05AI 评分39

CSL 支付 3.55 亿美元首付款共同开发 Alentis 的抗纤维化肾病与肝病药物

CSL to pay $355M upfront to co-develop Alentis’ kidney and liver drug

AI 导读

CSL 将支付 3.55 亿美元首付款,共同开发 Alentis Therapeutics 的抗纤维化药物。该协议涵盖肾病和肝病适应症,未来支付总额最高可达 12 亿美元。

正文

The Aus­tralian drug­mak­er CSL will pay $355 mil­lion for Alen­tis Ther­a­peu­tics’ an­ti-fi­bro­sis drug, plus as much as $1.2 bil­lion in fu­ture pay­ments.

Un­der the

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news